AU2013243388B2 - Methods and compositions for increasing red blood cells - Google Patents

Methods and compositions for increasing red blood cells Download PDF

Info

Publication number
AU2013243388B2
AU2013243388B2 AU2013243388A AU2013243388A AU2013243388B2 AU 2013243388 B2 AU2013243388 B2 AU 2013243388B2 AU 2013243388 A AU2013243388 A AU 2013243388A AU 2013243388 A AU2013243388 A AU 2013243388A AU 2013243388 B2 AU2013243388 B2 AU 2013243388B2
Authority
AU
Australia
Prior art keywords
polypeptide
bmp9
bmp
www
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013243388A
Other languages
English (en)
Other versions
AU2013243388A1 (en
Inventor
John Knopf
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2013243388A1 publication Critical patent/AU2013243388A1/en
Application granted granted Critical
Publication of AU2013243388B2 publication Critical patent/AU2013243388B2/en
Priority to AU2018202326A priority Critical patent/AU2018202326B2/en
Priority to AU2021201196A priority patent/AU2021201196A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013243388A 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells Ceased AU2013243388B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018202326A AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621154P 2012-04-06 2012-04-06
US61/621,154 2012-04-06
PCT/US2013/035305 WO2013152213A1 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202326A Division AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells

Publications (2)

Publication Number Publication Date
AU2013243388A1 AU2013243388A1 (en) 2014-10-23
AU2013243388B2 true AU2013243388B2 (en) 2018-01-25

Family

ID=49301055

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013243388A Ceased AU2013243388B2 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells
AU2018202326A Ceased AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A Abandoned AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018202326A Ceased AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A Abandoned AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Country Status (6)

Country Link
US (4) US9809636B2 (https=)
EP (2) EP3351260B1 (https=)
JP (4) JP6234993B2 (https=)
AU (3) AU2013243388B2 (https=)
CA (1) CA2869474C (https=)
WO (1) WO2013152213A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201412290D0 (en) * 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
EP3303387A2 (en) 2015-06-05 2018-04-11 Novartis AG Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20220021207A (ko) * 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015383A2 (en) * 2006-07-29 2008-02-07 University College Cardiff Consultants Limited Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
JPH08510446A (ja) * 1993-03-04 1996-11-05 クリエイティブ バイオモレキュルズ，インコーポレイテッド 組換え骨形成タンパク質を生成するための方法および組成物
JPH09501305A (ja) 1993-05-12 1997-02-10 ジェネティックス・インスティテュート・インコーポレイテッド Ｂｍｐ−１０組成物
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
EP1863518A2 (en) * 2005-03-30 2007-12-12 Wyeth Methods for stimulating hair growth by administering bmps
ES2649983T3 (es) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Antagonistas de activina-ActRIIa en su uso para promover el crecimiento óseo
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EA018221B1 (ru) 2007-02-09 2013-06-28 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
JP5719766B2 (ja) 2008-05-02 2015-05-20 アクセルロン ファーマ， インコーポレイテッド 血管新生および周皮細胞組成物を調節するための方法および組成物
CA2724525A1 (en) 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
DK2318028T3 (da) 2008-06-26 2020-05-04 Acceleron Pharma Inc Antagonister af opløselig activin-aktriia og anvendelser til øgning af røde blodcelleniveauer
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
AU2010282361B2 (en) 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
JP2012238811A (ja) 2011-05-13 2012-12-06 Toshiba Corp 半導体不揮発性記憶装置およびその製造方法
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CN104411720B (zh) * 2012-07-02 2018-05-11 协和发酵麒麟株式会社 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂
US20180125928A1 (en) 2015-05-13 2018-05-10 Celgene Corporation Treatment of beta-thalassemia using actrii ligand traps

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015383A2 (en) * 2006-07-29 2008-02-07 University College Cardiff Consultants Limited Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Also Published As

Publication number Publication date
US9809636B2 (en) 2017-11-07
JP6234993B2 (ja) 2017-11-22
EP3351260A1 (en) 2018-07-25
US20180186851A1 (en) 2018-07-05
US20200115428A1 (en) 2020-04-16
JP2019156858A (ja) 2019-09-19
US20210277082A1 (en) 2021-09-09
US10344066B2 (en) 2019-07-09
CA2869474C (en) 2021-08-03
US20130281371A1 (en) 2013-10-24
AU2013243388A1 (en) 2014-10-23
WO2013152213A1 (en) 2013-10-10
CA2869474A1 (en) 2013-10-10
AU2018202326A1 (en) 2018-04-26
EP2844272A4 (en) 2015-11-04
JP2015514115A (ja) 2015-05-18
AU2021201196A1 (en) 2021-03-11
JP2017190344A (ja) 2017-10-19
AU2018202326B2 (en) 2020-11-26
JP2021107453A (ja) 2021-07-29
EP2844272A1 (en) 2015-03-11
US10829534B2 (en) 2020-11-10
EP3351260B1 (en) 2022-07-13
US11807673B2 (en) 2023-11-07

Similar Documents

Publication Publication Date Title
US11807673B2 (en) Methods and compositions for increasing red blood cells
JP6968917B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
JP6860533B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
JP2020186277A (ja) 無効赤血球生成を処置するための方法および組成物
CA2964808C (en) Methods and compositions using gdf15 polypeptides for increasing red blood cells
US20230234998A1 (en) Twisted gastrulation polypeptides and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KUMAR, RAVINDRA; SURAGANI, NAGA VENKATA SAI RAJASEKHAR AND KNOPF, JOHN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired